[1]
|
Tumbarello, M., Sanguinetti, M., Montuori, E., Trecarichi, E.M., Posteraro, B., Fiori, B., Citton, R., D’Inzeo, T., Fadda, G., Cauda, R. and Spanu, T. (2007) Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Entero-bacteriaceae: Importance of inadequate initial antimicrobial treatment. Antimicrobial Agents and Chemotherapy, 51, 1987-1994. http://dx.doi.org/10.1128/AAC.01509-06
|
[2]
|
Blandino, G., Nicoletti, G. and Nicolosi, D. (2011) Susceptibility of molecularly characterized hospital-associated methicillin-resistant Staphylococcus aureus isolates to dalbavancin. Journal of Chemotherapy, 23, 306-307.
|
[3]
|
Chazan, B., Raz R., Teitler, N., Nitzan, O., Edelstein, H. and Colodner, R. (2009) Epidemiology and susceptibility to antimicrobials in community, hospital and long-term care facility bacteremia in northern Israel: A 6 year surveillance. Israel Medical Association Journal, 11, 592-597.
|
[4]
|
Kallen, A.J., Hidron, A.I., Patel, J. and Srinivasan, A. (2010) Multidrug resistance among gram-negative pathogens that caused healthcare-associated infections reported to the National Healthcare Safety Network, 2006-2008. Infection Control and Hospital Epidemiology, 31, 528-531. http://dx.doi.org/10.1086/652152
|
[5]
|
Moehario, L.H., Tjoa, E., Kiranasari, A., Ningsih, I., Rosana, Y. and Karuniawati, A. (2009) Trends in antimicrobial susceptibility of gram-negative bacteria isolated from blood in Jakarta from 2002 to 2008. Journal of Infection in Developing Countries, 3, 843-848.
|
[6]
|
Nicolosi, D., Nicolosi, V.M., Cappellani, A., Nicoletti, G. and Blandino, G. (2009) Antibiotic susceptibility profiles of uncommon bacterial species causing severe infections in Italy. Journal of Chemotherapy, 21, 253-260.
|
[7]
|
European Centre for Disease Prevention and Control (ECDC) (2012) Antimicrobial resistance surveillance in Europe 2011. Surveillance Report. www.ecdc.europa.eu
|
[8]
|
The European Committee on Antimicrobial Susceptibility testing (2010) Breakpoint tables for interpretation of MICs and zone diameters. Version 1.1, EUCAST. http://www.eucast.org/antimicrobial_susceptibility_testing/previous_versions_of_tables/
|
[9]
|
Clinical and Laboratory Standards Institute (2010) Performance standards for antimicrobial susceptibility testing. 20th Informational Supplement Document M100-S20, CLSI, Wayne.
|
[10]
|
Hombach, M., Wolfensberg, A., Kuster, S.P. and Böttger, E.C. (2013) Influence of clinical breakpoint changes from CLSI 2009 to EUCAST 2011 antimicrobial susceptibility testing guidelines on multidrug resistance rates of Gram-negative rods. Journal of Clinical Microbiology, 51, 2385-2387. http://dx.doi.org/10.1128/JCM.00921-13
|
[11]
|
Van der Bij, A.K., Van Dijk, K., Muilwijk, J., Thijsen, S.F., Notermans, D.W., De Greeff, S. and Van de Sande-Bruinsma, N. (2012) ISIS-AR study group. Clinical breakpoint changes and their impact on surveillance of antimicrobial resistance in Escherichia coli causing bacteraemia. Clinical Microbiology and Infection, 18, E466-E472. http://dx.doi.org/10.1111/j.1469-0691.2012.03996.x
|
[12]
|
Clinical and Laboratory Standards Institute (2013) Performance standards for antimicrobial susceptibility testing. 23rd Informational Supplement Document M100-S23, CLSI, Wayne.
|
[13]
|
The European Committee on Antimicrobial Susceptibility testing (2013) Breakpoint tables for interpretation of MICs and zone diameters. Version 3.1, EUCAST. http://www.eucast.org/antimicrobial_susceptibility_testing/previous_versions_of_tables/
|
[14]
|
Nordmann, P., Picazo, J.J., Mutters, R., Korten, V., Quintana, A., Laeuffer, J.M., Seak, J.C., Flamm, R.K. and Morrissey, I. (2011) on behalf of the COMPACT study group. Comparative activity of carbapenem testing: The COMPACT study. Journal of Antimicrobial Chemotherapy, 66, 1070-1078. http://dx.doi.org/10.1093/jac/dkr056
|
[15]
|
Schito, G.C., Gualco, L., Naber, K.G., Botto, H., Palou, J., Mazzei, T. and Marchese, A. (2010) Do different susceptibility breakpoints affect the selection of antimicrobials for treatment of uncomplicated cystitis? Journal of Chemotherapy, 22, 345-354.
|
[16]
|
Hombach, M., Muottet, B. and Bloemberg, G.V. (2013) Consequences of revised CLSI and EUCAST guidelines for antibiotic susceptibility patterns of ESβL-and AmpC β-lactamase-producing clinical Enterobacteriaceae isolates. Journal of Antimicrobial Chemotherapy, 68, 2092-2098.
|
[17]
|
Hawser, S.P., Badal, R.E., Bouchillon, S.K., Hoban, D.J. and Hsueh, P.R. (2010) Comparison of CLSI 2009, CLSI 2010 and EUCAST cephalosporin clinical breakpoints in recent clinical isolates of Escherichia coli, Klebsiellap-neumoniae and Klebsiellaoxytoca from the SMART Global Surveillance Study. International Journal of Antimicrobial Agents, 36, 293-294. http://dx.doi.org/10.1016/j.ijantimicag.2010.05.012
|
[18]
|
Kristo, I., Pitiriga, V., Poulou, A., Zarkotou, O., Kimouli, M., Pournaras, S. and Tsakris, A. (2013) Susceptibility patterns to extended-spectrum cephalosporins among Enterobacteriaceae harbouring extended-spectrum β-lactamases using the update Clinical and Laboratory Standards Institute interpretative criteria. International Journal of Antimicrobial Agents, 41, 383-387. http://dx.doi.org/10.1016/j.ijantimicag.2012.12.003
|
[19]
|
Rodriguez-Baño, J., Picó, E., Navarro, M.D., López-Cerero, L., Pascual á. and the ESBL-REIPI Group (2012) Impact of changes in CLSI and EUCAST breakpoints for susceptibility in bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli. Clinical Microbiology and Infection, 18, 894-900. http://dx.doi.org/10.1111/j.1469-0691.2011.03673.x
|